Literature DB >> 20080869

Epidermal growth factor receptor is an obligatory intermediate for oxytocin-induced cyclooxygenase 2 expression and prostaglandin F2 alpha production in bovine endometrial epithelial cells.

Narayanan Krishnaswamy1, Nicolas Lacroix-Pepin, Pierre Chapdelaine, Hiroaki Taniguchi, Gilles Kauffenstein, Arpita Chakravarti, Ghislain Danyod, Michel A Fortier.   

Abstract

Oxytocin (OT) triggers the luteolytic pulses of prostaglandin F(2 alpha) (PGF(2 alpha)) from the endometrial epithelial cells in ruminants. We have proposed that the embryonic signal interferon-tau exerts its antiluteolytic effect by disrupting the OT signaling axis. Accordingly, we have attempted to define the signaling pathway of OT-induced PGF(2 alpha) production in the bovine endometrium using our newly characterized epithelial cell line (bEEL). OT receptor was coupled to the classical G alpha(q) pathway as evidenced by calcium release and activation of phospholipase C. Similarly, OT-induced PGF(2 alpha) production was mediated through the canonical ERK1/2 pathway. Because of the importance of receptor and nonreceptor tyrosine kinases in G protein-coupled receptor signaling, we studied the role of epidermal growth factor receptor (EGFR), c-Src, and phosphoinositide 3-kinase (PI3K) on OT-induced PGF(2 alpha) production in association with cyclooxygenase 2 (COX2) expression and ERK1/2 and Akt phosphorylation. The EGFR inhibitor AG1478 (10 microm) nearly abolished basal and OT-induced PGF(2 alpha) production and down-regulated COX2 expression and ERK1/2 phosphorylation. Because the transactivated EGFR can serve as a ligand for the signaling proteins with Src homology 2 (SH2) domain, we hypothesized a role for c-Src and PI3K in OT-induced PGF(2 alpha) production. Inhibitors of c-Src (PP2, 10 microm) and PI3K (LY294002, 25 microm) produced a significant decrease in OT-induced PGF(2 alpha) production and reduced COX2 expression. Also, PP2, but not LY294002, decreased OT-induced ERK1/2 phosphorylation. Because LY294002 did not affect ERK1/2 phosphorylation, but inhibited PGF(2 alpha) production and down-regulated COX2 expression, it is likely that the Akt pathway is also involved in PGF(2 alpha) production. Thus, EGFR may simultaneously activate c-Src and PI3K to amplify the OT signaling to increase the output of PGF(2 alpha) in bEEL cells.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20080869     DOI: 10.1210/en.2009-1304

Source DB:  PubMed          Journal:  Endocrinology        ISSN: 0013-7227            Impact factor:   4.736


  5 in total

1.  The Prostaglandin F Synthase Activity of the Human Aldose Reductase AKR1B1 Brings New Lenses to Look at Pathologic Conditions.

Authors:  Eva Bresson; Nicolas Lacroix-Pépin; Sofia Boucher-Kovalik; Pierre Chapdelaine; Michel A Fortier
Journal:  Front Pharmacol       Date:  2012-05-25       Impact factor: 5.810

2.  High Oxytocin Receptor Expression Linked to Increased Cell Migration and Reduced Survival in Patients with Triple-Negative Breast Cancer.

Authors:  Huiping Liu; Markus Muttenthaler
Journal:  Biomedicines       Date:  2022-07-05

3.  Global endometrial transcriptomic profiling: transient immune activation precedes tissue proliferation and repair in healthy beef cows.

Authors:  Cathriona Foley; Aspinas Chapwanya; Christopher J Creevey; Fernando Narciandi; Derek Morris; Elaine M Kenny; Paul Cormican; John J Callanan; Cliona O'Farrelly; Kieran G Meade
Journal:  BMC Genomics       Date:  2012-09-18       Impact factor: 3.969

4.  Cyclooxygenase-2 inhibitor is a robust enhancer of anticancer agents against hepatocellular carcinoma multicellular spheroids.

Authors:  Jie Cui; Ya-Huan Guo; Hong-Yi Zhang; Li-Li Jiang; Jie-Qun Ma; Wen-Juan Wang; Min-Cong Wang; Cheng-Cheng Yang; Ke-Jun Nan; Li-Ping Song
Journal:  Onco Targets Ther       Date:  2014-02-24       Impact factor: 4.147

5.  Central role for protein kinase C in oxytocin and epidermal growth factor stimulated cyclooxygenase 2 expression in human myometrial cells.

Authors:  Elien Wouters; Claire A Hudson; Craig A McArdle; Andrés López Bernal
Journal:  BMC Res Notes       Date:  2014-06-10
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.